Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection USP, 50 mg/mL single-dose vials, the company announced through an exchange filing.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States.
The group now has 368 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Kerala CM Pinarayi Vijayan Compares RSS To Zionists In Israel During Speech At Kannur Public Meet
TNPSC Group 4 Result 2025 To Be Declared Soon On tnpsc.gov.in; Check Details Here
.jpg)
Pimpri-Chinchwad: PCMC Collects ₹607 Crore Property Tax In First Half Of FY 2025-26
'Central Government Committed To Fulfil Ladakh’s Hopes,' Says Ladakh LG Kavinder Gupta After Review Of Law And Order
